{"id":"alcaftadine-0-25-ophthalmic-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Ocular irritation"},{"rate":null,"effect":"Conjunctival hyperemia"},{"rate":null,"effect":"Eye discomfort"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Alcaftadine works by competitively antagonizing H1 histamine receptors on mast cells and other immune cells in ocular tissues, preventing histamine release and reducing allergic inflammation. This mechanism provides rapid relief of itching and other allergic symptoms in allergic conjunctivitis. The drug's selectivity for H1 receptors and topical ocular delivery minimize systemic effects.","oneSentence":"Alcaftadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:20:50.673Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Allergic conjunctivitis (itching associated with allergic conjunctivitis)"}]},"trialDetails":[{"nctId":"NCT02555761","phase":"","title":"Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea","status":"COMPLETED","sponsor":"Allergan","startDate":"2015-10-19","conditions":"Conjunctivitis, Allergic","enrollment":3423},{"nctId":"NCT00889330","phase":"PHASE3","title":"Safety and Efficacy Study of a Eye Drop for Eye Allergy","status":"COMPLETED","sponsor":"Vistakon Pharmaceuticals","startDate":"2009-04","conditions":"Allergic Conjunctivitis","enrollment":60},{"nctId":"NCT01732757","phase":"PHASE4","title":"A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2012-11","conditions":"Conjunctivitis, Allergic","enrollment":157},{"nctId":"NCT01470118","phase":"PHASE4","title":"A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2011-10","conditions":"Conjunctivitis, Allergic","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":8,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["LASTACAFT®"],"phase":"marketed","status":"active","brandName":"alcaftadine 0.25% ophthalmic solution","genericName":"alcaftadine 0.25% ophthalmic solution","companyName":"Allergan","companyId":"allergan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Alcaftadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses in the eye. Used for Allergic conjunctivitis (itching associated with allergic conjunctivitis).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}